Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 May 2026

Naito Yoichi

Abstract excerpt

BRAF is a serine/threonine kinase that functions as a key component of the RAS/RAF/MEK/ERK (MAPK) signaling pathway and is recognized as an important oncogenic driver across multiple cancers. BRAF mutations are detected in a variety of malignancies including melanoma, thyroid cancer, colorectal cancer, non-small cell lung cancer, and biliary tract cancer. Among them, the V600 mutation results in constitutive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasms
Share to Protein Kinase Inhibitors
Share to Proto-Oncogene Proteins B-raf

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to BRAF gene

Share to EGFR gene

Share to Molecular Targeted Therapy

Share to Mutation

Source

Identifiers

PMID: 42237509

Genes

BRAF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[BRAF-Mutant Solid Tumor].PMID 42237509Read ↗

Defining and Targeting BRAF Mutations in Solid Tumors.Semantic proximity Read ↗

BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical ApplicationsSemantic proximity Read ↗

[BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma].Semantic proximity Read ↗

BRAF as a target for cancer therapy.Semantic proximity Read ↗

[Expert consensus on BRAF inhibitors in the treatment of malignant solid tumors (2024 edition)].Semantic proximity Read ↗

[Progress of anti-tumor study based on BRAF].Semantic proximity Read ↗

BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Semantic proximity Read ↗

[Therapeutic Strategy for BRAF-Mutated Cancer].Semantic proximity Read ↗

Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid TumorsSemantic proximity Read ↗

Targeting Oncogenic BRAF: Past, Present, and FutureSemantic proximity Read ↗

Targeting the multifaceted BRAF in cancer: New directions.Semantic proximity Read ↗

BRAF Mutations: Oncogenic Drivers in Solid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.